Inventor
SHITARA KENYA
JP56 patents
⚠️ This page may combine multiple inventors who share the name “SHITARA KENYA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
KYOWA HAKKO KOGYO KK
28 patentsUS6437098B1Aug 20, 2002
Human chimeric antibody specific for the ganglioside GD3
KYOWA HAKKO KOGYO KK87 citations99
US5866692AFeb 2, 1999
Process for producing humanized chimera antibody
KYOWA HAKKO KOGYO KK323 citations99
US5750078AMay 12, 1998
Process for producing humanized chimera antibody
KYOWA HAKKO KOGYO KK156 citations99
US7064191B2Jun 20, 2006
Process for purifying antibody
KYOWA HAKKO KOGYO KK89 citations98
US6989145B2Jan 24, 2006
Recombinant antibody and antibody fragment
KYOWA HAKKO KOGYO KK93 citations98
US5830470ANov 3, 1998
Humanized antibodies to ganglioside GM2
KYOWA HAKKO KOGYO KK112 citations98
US6986890B1Jan 17, 2006
Anti-human VEGF receptor Flt-1 monoclonal antibody
KYOWA HAKKO KOGYO KK100 citations97
US7504104B2Mar 17, 2009
Human CDR-grafted antibody and antibody fragment thereof
KYOWA HAKKO KOGYO KK28 citations96
US6872392B2Mar 29, 2005
Humanized antibodies
KYOWA HAKKO KOGYO KK44 citations96
US6423511B1Jul 23, 2002
Humanized antibodies
KYOWA HAKKO KOGYO KK42 citations96
US5807548ASep 15, 1998
Method of treating cancer using a chimera antibody
KYOWA HAKKO KOGYO KK30 citations96
US4892935AJan 9, 1990
Anti-human pulmonary carcinoma monoclonal antibody
KYOWA HAKKO KOGYO KK47 citations93
US7498415B2Mar 3, 2009
Recombinant antibody against human insulin-like growth factor
KYOWA HAKKO KOGYO KK48 citations92
US7438911B2Oct 21, 2008
Antibody against human insulin-like growth factor
KYOWA HAKKO KOGYO KK33 citations92
US6617160B1Sep 9, 2003
Anti-human VEGF receptor Flt-1 monoclonal antibody
KYOWA HAKKO KOGYO KK24 citations92
US6042828AMar 28, 2000
Humanized antibodies to ganglioside GM2
KYOWA HAKKO KOGYO KK16 citations92
US5939532AAug 17, 1999
Humanized antibodies to ganglioside GM2
KYOWA HAKKO KOGYO KK22 citations92
US7052693B2May 30, 2006
Anti-human VEGF receptor FLT-1 monoclonal antibody
KYOWA HAKKO KOGYO KK20 citations91
US7253263B1Aug 7, 2007
Complementarity determining region-grafted antibody against ganglioside GD3 and derivative of antibody against ganglioside GD3
KYOWA HAKKO KOGYO KK37 citations90
US7404953B2Jul 29, 2008
Methods using eosinophil-specific apoptosis inducer
KYOWA HAKKO KOGYO KK6 citations74
US5874255AFeb 23, 1999
DNA encoding humanized antibodies specific for the ganglioside GM2
KYOWA HAKKO KOGYO KK9 citations74
US5552291ASep 3, 1996
Anti-human pulmonary adenocarcinoma specific monoclonal antibody
KYOWA HAKKO KOGYO KK7 citations74
US7045129B2May 16, 2006
Method of treating cancer including administering a human chimeric antibody specific for the ganglioside GD3
KYOWA HAKKO KOGYO KK2 citations63
US6965024B2Nov 15, 2005
Process for producing humanized chimera antibody
KYOWA HAKKO KOGYO KK1 citations63
US6495666B2Dec 17, 2002
Polypeptide composing human chimeric antibody
KYOWA HAKKO KOGYO KK1 citations63
US5169938ADec 8, 1992
Anti-T cell receptor γ-chain monoclonal antibody
KYOWA HAKKO KOGYO KK3 citations63
US5081032AJan 14, 1992
Anti-human pulmonary adenocarcinoma monoclonal antibody
KYOWA HAKKO KOGYO KK3 citations63
US5580740ADec 3, 1996
Antihuman pulmonary adenocarcinoma monoclonal antibody
KYOWA HAKKO KOGYO KK1 citations52
KYOWA HAKKO KIRIN CO LTD
13 patentsUS7994290B2Aug 9, 2011
Effector function enhanced recombinant antibody composition
KYOWA HAKKO KIRIN CO LTD55 citations96
US7923538B2Apr 12, 2011
Recombinant antibody composition
KYOWA HAKKO KIRIN CO LTD84 citations96
US7842797B2Nov 30, 2010
Human CDR-grafted antibody and antibody fragment thereof
KYOWA HAKKO KIRIN CO LTD14 citations92
US7691568B2Apr 6, 2010
Antibody composition-containing medicament
KYOWA HAKKO KIRIN CO LTD39 citations92
US7666418B2Feb 23, 2010
Method for treating Th2-mediated disease
KYOWA HAKKO KIRIN CO LTD22 citations92
US7851601B2Dec 14, 2010
Monoclonal antibody capable of binding to heparin-binding epidermal growth factor-like growth factor
KYOWA HAKKO KIRIN CO LTD7 citations72
US7615215B2Nov 10, 2009
Anti-human VEGF receptor Flt-1 monoclonal antibody
KYOWA HAKKO KIRIN CO LTD1 citations61
US10590203B2Mar 17, 2020
Human CDR-grafted antibody and antibody fragment thereof
KYOWA HAKKO KIRIN CO LTD0 citations52
US10131711B2Nov 20, 2018
Human CDR-grafted antibody and antibody fragment thereof
KYOWA HAKKO KIRIN CO LTD0 citations52
US9051371B2Jun 9, 2015
Human CDR-grafted antibody and antibody fragment thereof
KYOWA HAKKO KIRIN CO LTD0 citations52
US8900584B2Dec 2, 2014
Human CDR-grafted antibody and antibody fragment thereof
KYOWA HAKKO KIRIN CO LTD0 citations52
US9475886B2Oct 25, 2016
Recombinant antibody composition
KYOWA HAKKO KIRIN CO LTD0 citations51
US7615214B2Nov 10, 2009
Anti-human VEGF receptor Flt-1 monoclonal antibody
KYOWA HAKKO KIRIN CO LTD0 citations51
SHITARA KENYA
6 patentsUS8632996B2Jan 21, 2014
Method for producing recombinant antibody and antibody fragment thereof
SHITARA KENYA4 citations83
US8491902B2Jul 23, 2013
Medicament comprising recombinant antibody against chemokine receptor CCR4
SHITARA KENYA6 citations82
US8143058B2Mar 27, 2012
Human CDR-grafted antibody and antibody fragment thereof
SHITARA KENYA1 citations62
US8883981B2Nov 11, 2014
Recombinant antibody composition
SHITARA KENYA3 citations61
US8197814B2Jun 12, 2012
Method for treating the Th2-mediated disease
SHITARA KENYA3 citations61
US8492526B2Jul 23, 2013
Effector function enhanced recombinant antibody composition
SHITARA KENYA0 citations50
UNIV TOKAI
1 patentNAKAMURA KAZUYASU
1 patentMEKADA EISUKE
1 patentShowing the top 50 of 56 patents by PatentIndex Score.